AstraZeneca and Sandoz resolve Faslodex patent litigation
AstraZeneca announced today that it has entered into an agreement with Sandoz to resolve patent litigation between the two companies.
As reported by Reuters, the companies have agreed to resolve the dispute centring on Sandoz’s generic version of Faslodex (fulvestrant).
Fulvestrant, a hormonal therapy drug used to treat breast cancer, became the centre of the dispute after Sandoz filed an Abbreviated New Drug Application with the US Food and Drug Administration (FDA).
Sandoz had applied for FDA approval before the expiration of AstraZenca’s US patent numbers 6,774,122; 7,456,160; 8,329,680; and 8,466,139.
The patents are due to expire in January 2021, but have a pediatric exclusivity stretching until July 2021.
AstraZeneca sued Sandoz at the US District Court for the District of New Jersey in 2014.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk